Welcome to our dedicated page for Nls Pharmaceutic SEC filings (Ticker: NLSPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through NLS Pharmaceutics’ labyrinth of drug-development disclosures is no small task. Every 10-K packs dense clinical-trial tables, patent timelines, and risk factors that stretch far beyond routine revenue lines. Investors tracking how the Swiss biotech funds Phase 2 narcolepsy studies or books milestone payments often need to cross-reference amendments, 8-K updates, and dozens of Form 4 notices from scientific founders. If you have ever searched “where can I find NLS Pharmaceutics’ quarterly earnings reports?” or “what does NLS Pharmaceutics report in their SEC filings?” you already know the challenge.
Stock Titan brings clarity. Our AI reads each NLS Pharmaceutics quarterly earnings report 10-Q filing and NLS Pharmaceutics annual report 10-K simplified, then delivers plain-English highlights—cash runway, R&D spend, trial-enrollment progress—within seconds. Real-time alerts surface NLS Pharmaceutics Form 4 insider transactions real-time, while smart explanations turn opaque NLS Pharmaceutics 8-K material events explained into concise summaries you can act on. Whether you’re comparing pay in the latest NLS Pharmaceutics proxy statement executive compensation or reviewing NLS Pharmaceutics insider trading Form 4 transactions, the platform answers naturally voiced questions and links directly to the source documents.
- Track NLS Pharmaceutics executive stock transactions Form 4 in context of upcoming data releases.
- Spot trends with NLS Pharmaceutics earnings report filing analysis across quarters.
- Speed up due diligence by understanding NLS Pharmaceutics SEC documents with AI that flags pipeline catalysts and patent expirations.
From initial S-1 amendments to the latest disclosures, every NLS Pharmaceutics SEC filings explained simply is updated the moment it hits EDGAR—so you’re never a step behind.
Form 8-K Item 8.01 – Other Events
On 30 June 2025, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) disclosed pre-clinical data for SKNY-1, an oral therapeutic it is under definitive agreement to acquire from SKNY Pharmaceuticals. In a zebrafish model simulating human obesity and craving behaviour, six-day oral dosing produced an approximate 30 % body-weight reduction, leaving treated animals 10 % lighter than healthy controls while preserving muscle density. Metabolic indicators improved, including higher ventilation rate, normalised liver fat, and restoration of both LDL and HDL cholesterol to healthy levels without raising circulating triglycerides.
Behaviourally, SKNY-1 dose-dependently suppressed high-calorie consumption, reduced compulsive food seeking, and eliminated nicotine-seeking even under stress. The compound also normalised leptin and ghrelin and, at lower doses, reduced elevated dopamine linked to reward cravings.
The company states that these results warrant advancement into IND-enabling studies and positions SKNY-1 as a potential cornerstone asset once the acquisition closes, citing a combined obesity and smoking market opportunity exceeding US$200 billion.
The filing does not include human data, transaction financials, development costs, or projected timelines.
NLS Pharmaceutics Ltd. – Schedule 13D filing (NLSPW)
Chairman Ronald Hafner has filed a Schedule 13D disclosing beneficial ownership of 557,131 common shares, equal to 13.2 % of the company’s 4,097,641 outstanding shares. Mr. Hafner possesses sole voting and dispositive power over the entire position; no shares are held jointly.
Capital deployment was entirely from personal funds. The filing details multiple transactions that built the position:
- Equity Purchase Agreement (10-Oct-2024): acquired 100,807 common shares plus 100,807 five-year warrants (exercise $4.25) at a combined price of $3.97.
- Warrant Amendment (9-Oct-2024): received pre-funded warrants for 1,925 shares, exercisable at CHF 0.80.
- Debt Purchase Agreement (10-Oct-2024): obtained 173,173 convertible preferred shares (conversion price $4.96) as part of a $4 m debt restructuring.
- Put-Call Agreement (Feb-2025): option exercised leading to purchase of 37,783 preferred shares for $150,000.
- Debt settlements: 111,637 common shares transferred from CEO Alexander Zwyer (7-Feb-2025) and 17,782 shares transferred from Magnetic Rock Investment AG (21-Feb-2025).
Intent: The shares are held for investment; no activist agenda is disclosed. The agreements grant limited participation rights (up to 50 % of future offerings for one year) but do not impose voting covenants. No criminal or civil proceedings are reported against the filer.
For investors, the filing signals material insider confidence and establishes Mr. Hafner as the company’s largest known shareholder, potentially aligning board decisions with shareholder value creation. No immediate dilution or earnings impact is indicated, but future conversions of preferred shares and warrant exercises could expand the float.
Form F-4/A Amendment No. 4 outlines the proposed all-share merger between NLS Pharmaceutics Ltd. ("NLS") and Kadimastem Ltd., an Israeli cell-therapy company listed on TASE. The transaction will be executed through the merger of NLS Pharmaceutics (Israel) Ltd., a wholly-owned subsidiary of NLS, into Kadimastem, with Kadimastem surviving. At the effective time, each Kadimastem ordinary share converts into NLS common shares using an exchange ratio designed to give Kadimastem shareholders approximately 80 % ownership of the fully-diluted post-merger equity (initial target 85 %), leaving legacy NLS holders with roughly 20 %.
Key structural elements include:
- Security issuance: Registration covers an undisclosed maximum number of NLS common shares and pre-funded warrants to satisfy U.S. 9.99 % beneficial-ownership limits.
- Capital actions: Two ordinary capital increases are sought to create sufficient common and preferred share capacity.
- Corporate re-branding & listing: Post-closing entity to trade on Nasdaq as NewcelX Ltd. under new tickers "NCEL" and "NCELW"; NLS has filed the required additional-listing application.
- Governance changes: Current NLS directors and officers will resign (except co-founder Alexander Zwyer, who retains a board seat for one year). Kadimastem’s board and executives will assume comparable roles in the combined company.
- Asset disposition & CVR: All non-DOXA assets of NLS are earmarked for sale, with net proceeds distributed to pre-merger NLS shareholders/warrant-holders via contingent value rights.
- Financing adjustments: $5.7 million raised by NLS from Oct-24 to Mar-25 is applied to the "Investment Proceeds Adjustment" that reduces Kadimastem’s final equity percentage.
- Convertible debt: Specified Kadimastem-related loans (US$1.7 million and NIS 3.4 million) convert to equity at closing.
The NLS extraordinary shareholders’ meeting will seek advisory approval of the merger and the necessary capital increases. Completion remains subject to SEC effectiveness, Nasdaq approval, and customary closing conditions.
FAQ
What is the current stock price of Nls Pharmaceutic (NLSPW)?
What is the primary focus of NLS Pharmaceutics?
Which therapeutic areas does NLS Pharmaceutics target?
How does NLS Pharmaceutics drive innovation?
What distinguishes the R&D strategy of NLS Pharmaceutics?
How does the company maintain regulatory compliance?
What are the key strengths of NLS Pharmaceutics?
How is NLS Pharmaceutics positioned in the competitive landscape?
What role does intellectual property play in NLS Pharmaceutics' strategy?
